Lilly Research Laboratories et al.; FDA Withdraws Approval of 22 New Drug Applications and 36 Abbreviated New Drug Applications

Summary

The US Food and Drug Administration (FDA) has withdrawn the approval of 22 new drug applications (NDAs) and 36 abbreviated new drug applications (ANDAs) following written notifications from the applicants that the corresponding drug products are no longer commercially available.